Filing Flows › TG Therapeutics (TGTX) › Q2 2026
TG Therapeutics (TGTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
TG Therapeutics (TGTX) reported revenue of $240M for the second quarter 2026 (Q2 2026), +70% from a year earlier and +17% from the quarter before. Operating margin was 9.0%, net earnings $7.8M (3.2% of revenue).
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $240M | +17% | +70% |
| Operating profit | $21.7M | -38% | -38% |
| Net earnings | $7.8M | -61% | -72% |
| Operating cash flow | $39.3M | — | +428% |
| Free cash flow | $39.0M | — | +427% |
What changed
Revenue was $240.3M in Q2 2026, up 70% year over year and up 17% from the previous quarter. Product was the largest line at 98% of revenue. Product added $97.0M year over year (up 70%), 98% of the total change.
Operating profit was $21.7M, a 9.0% margin (down 15.7 points year over year). Operating profit fell $13.2M even though revenue rose $99.2M versus Q2 2025, so costs grew faster than sales. Total costs grew 106% against revenue growth of 70%. The fastest-growing cost line was Research & development (+200%). Net earnings were $7.8M, down 72% year over year. The effective tax rate was 24.0%.
Operating cash flow was $39.3M (up 428% year over year), 505% of net earnings. Non-cash charges added back $53K of depreciation and amortization and $27.9M of share-based compensation. Working capital and other items added $3.6M. Capital expenditures of $293K left free cash flow of $39.0M.
Questions
What was TG Therapeutics' revenue in the second quarter 2026?
TG Therapeutics (TGTX) reported revenue of $240M for the second quarter 2026 (Q2 2026), +70% from a year earlier and +17% from the quarter before.
Was TG Therapeutics profitable in the second quarter 2026?
Operating profit was $21.7M (9.0% of revenue) and net earnings $7.8M.
Source: TG Therapeutics 10-Q on SEC EDGAR.